Back to Search Start Over

Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma

Authors :
Iglesias, Pedro
Biagetti, Betina
Araújo-Castro, Marta
Alcázar, Victoria
Guerrero-Pérez, Fernando
Rivero, Noelia
Casteràs, Anna
García Izquierdo, Belén
García Gómez, Carlos
Viedma Torres, Víctor
Pascual-Corrales, Eider
Pavón, Isabel
Villabona, Carles
Cordido, Fernando
Díez, Juan J.
Iglesias, Pedro
Biagetti, Betina
Araújo-Castro, Marta
Alcázar, Victoria
Guerrero-Pérez, Fernando
Rivero, Noelia
Casteràs, Anna
García Izquierdo, Belén
García Gómez, Carlos
Viedma Torres, Víctor
Pascual-Corrales, Eider
Pavón, Isabel
Villabona, Carles
Cordido, Fernando
Díez, Juan J.
Publication Year :
2022

Abstract

[Abstract] Background: In recent years, dopamine agonists (DAs) have become an attractive therapeutic option to prevent both tumor growth and post-surgical tumor remnant growth in clinically non-functioning pituitary adenoma (NFPA). Aim: To analyze our experience on the effect of cabergoline (CAB) on tumor remnant after initial surgery in NFPA patients. Patients and methods: A retrospective and multicenter study of NFPA patients with tumor remnant after surgery treated with CAB was performed. Results: From a total of 142 NFPA patients (79 men, 55.2%; mean age 57.2 ± 14.2 year) who underwent surgery, we selected 62/142 (43.7%) patients (32 men, 51.6%; mean age 59.3 ± 13.9 year) with tumor persistence (TP) after surgery. In 22/62 (35.5%) TP patients CAB was used (CAB group), while the rest of the patients (40/62, 64.5%) underwent active surveillance [observation (OBS) group)]. The maximum diameter of the tumor remnant did not change significantly in either the CAB group [11.5 (6.0-16.9) mm vs. 12.0 (7.0-15.0) mm, p = 0.85) or the OBS group [8.5 (6.0-13.7) mm vs. 9.0 (6.2-14.0) mm, p = 0.064) at the end of the follow-up [13 (10.5-17) vs. 77.5 (50.2-107.2) months, CAB vs. OBS group; p < 0.001]. At the end of the treatment period with CAB most of the patients (n = 20/22, 90.9%) showed no progression of the tumor remnant [stable disease, SD (n = 17/22, 77.2%) and partial response, PR (n = 3/22, 13.6%)], while 2/22 patients (9.1%) exhibited progression. Similar response rates were observed in the OBS group [SD (n = 32/40, 80%), PR (n = 2/40, 5%), and progression (n = 6/40, 15%)]. Although no statistically significant differences (p = 0.42) were found in these responses, the percentage of progression was 1.65 times higher in the OBS group compared to the CAB group. On the contrary, the percentage of PR was 2.72 times higher in the CAB group compared to the OBS group, despite a significantly shorter follow-up period in the CAB group. Conclusion: Although the present study sh

Details

Database :
OAIster
Notes :
0167-594X, http://hdl.handle.net/2183/32378, Iglesias P, Biagetti B, Araujo-Castro M, Alcázar V, Guerrero-Pérez F, Rivero N, Casteràs A, Gómez CG, Izquierdo BG, Torres VV, Pascual-Corrales E, Pavón I, Villabona C, Cordido F, Díez JJ. Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma. J Neurooncol. 2022 Nov;160(2):351-359., English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1372989782
Document Type :
Electronic Resource